THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rod@welchco.com
S U M M A R Y
DIARY: March 3, 2014 04:44 PM Monday;
Rod Welch
VA letter request Progress Notes meeting on Feb 13.
1...Summary/Objective
2...Cold Symptoms Subside Evidence Not Caused Atorvastatin Ezetimibe
3...Progress Notes Request for Meeting San Francisco VA Medical Center
..............
Click here to comment!
CONTACTS
SUBJECTS
VA Prescribe Atorvastin 10 MG Trial 4 Weeks Evaluate Side Effects In
6003 -
6003 - ..
6004 - Summary/Objective
6005 -
600501 - Follow up ref SDS 65 0000. ref SDS 63 0000.
600502 -
600503 -
600504 -
600505 -
600506 -
600507 -
600509 - ..
6006 -
6007 -
6008 - Background
6009 -
6010 -
601001 - Lab on 131015, showing cholesterol remained high, 131015 0724,
601002 - ref SDS 37 BE6O, conflict with increased exercise and weight loss,
601003 - discussed in the letter to the medical team yesterday on 131016 1632.
601004 - ref SDS 38 IW57
601006 - ..
601007 - On 131017 1000 VA medical chart Progress Notes assessment report
601008 - patient status CAD stable, asymptomatic. hyperlipidemia not
601009 - controlled. ref SDS 39 T24N
601011 - ..
601012 - On 131017 1000 Doctor Egan proposed referring patient for clinical
601013 - trial to reduce cholesterol with new "targeted" drugs. ref SDS 39 179N
601015 - ..
601016 - On 131017 1000 VA medical chart Progress Notes assessment report
601017 - patient status hyperlipidemia not controlled, ref SDS 39 PSXT; Doctor
601018 - Egan makes referral to SF VA Medical Center for consult on
601019 - participation clinical trials, ref SDS 39 EU9F, with experimental
601020 - agents such as AMG 145 and REGN 727 to resolve multiple statin
601021 - intolerances. ref SDS 39 CN4H
601023 - ..
601024 - On 131103 received letter from VA SF Medical Center scheduling meeting
601025 - on 131121 1000, to consider clinical trial for lowering cholesteral.
601026 - ref SDS 41 YT4N
601028 - ..
601029 - On 131112 New York Times published several articles reporting that the
601030 - day before on 131113, American Heart Association published new
601031 - guidelines for treating CAD patients that expand use of statin
601032 - medication regardless of cholesterol levels, ref SDS 42 0001, and
601033 - further raise the LDL 70 to LDL 190, as a target for cardiovascular
601034 - risk. ref SDS 42 CW6H
601036 - ..
601037 - On 131114 New York Times published several articles reporting that the
601038 - day before on 131113, American Heart Association published new
601039 - guidelines for treating CAD patients. ref SDS 43 SH6G
601041 - ..
601042 - On 131121 1604 meeting with Doctor Alba at San Francisco Medical
601043 - Center - prescribed Atorvastatin 20 mg 4-week trial and evaluate
601044 - adding Zetia 10 mg, schedule follow up on 131219 0930. ref SDS 44 6H6K
601046 - ..
601047 - On 131121 1604 in another record later today, VA prescription RX #
601048 - 5674471 for Atorvastatin 20 mg has been ordered. ref SDS 45 GH5M
601050 - ..
601051 - On 131125 0005 letter from Karen reports VA work plan to take statin
601052 - drug low dose Atvorstatin 10 mg for 4 weeks, then add Zetia 10 mg in
601053 - clinical trial for lowering cholesterol. ref SDS 47 V154
601055 - ..
601056 - On 131125 0005 research seems to indicate this clincial trial of low
601057 - dose Atorvasatatin 10 mg with Zeitia 10 mg has lowered cholesterol LDL
601058 - 70.
601060 - ..
601061 - On 131205 1448 received new prescription for Atvorstatin 20 mg,
601062 - ordered by Doctor Alba today for 4-week trial to assess side effects
601063 - for adding 2nd drug, Zetia 10 mg to lower LDL 249. ref SDS 48 GH5M
601065 - ..
601066 - On 131216 0028 letter to Doctor Alba submit agenda for meeting at VA
601067 - SFMC on 131219. ref SDS 49 HY6O
601069 - ..
601070 - On 131219 0930 meeting Doctor Alba at San Francisco VA Medical Center
601071 - ordered Ezedimibe 10 mg prescription for adding to Atorvastatin, and
601072 - ordered blood test to evaluate changes in lipid profile. 131219 0930,
601073 - ref SDS 50 NJ6G
601075 - ..
601076 - On 131230 1450, received Ezetimibe in US mail, ref SDS 51 5N3O,
601077 - ordered by Doctor Alba on 131219, 131219 0930, ref SDS 50 6H6K; begin
601078 - trial to manage cholesterol with Atorvastatin 10 mg and Ezetimibe 10
601079 - mg, planned during meeting at VA on 131121 0930. ref SDS 44 6H6K
601081 - ..
601082 - On 140114 0845 letter to Diana request Progress Notes meeting 131219,
601083 - ref SDS 52 HY6O, and ask about expanding scope pending lab to include
601084 - LDL-P. ref SDS 52 2140
601086 - ..
601087 - On 140115 1842 letter Diana will look for Progress Notes meeting
601088 - 131219, ref SDS 53 HY6O; investigating prospects for ordering lab test
601089 - LDL-P, ref SDS 53 CE80; VA claims patient cholesterol and LDL are above
601090 - target. ref SDS 53 CE91 VA further claims testing LDL-P not effective
601091 - in this case because LDL-C is not optimal. ref SDS 53 FF4H
601093 - ..
601094 - On 140116 0814 letter thanks Doctor Alba for investigting to find
601095 - Progress Notes for meeting at VA on 131219. ref SDS 54 HY6O Cite
601096 - research indicating patient with discordant LDL-C high and LDL-P low,
601097 - shown in patient lab on 131015, constitutes least risk for
601098 - arterialsclorosis disorder, CVD, mycardial infarction. ref SDS 54 735Y
601100 - ..
601101 - On 140128 1327 letter asks again about Progress Notes meeting 131219,
601102 - ref SDS 55 HY6O; report hiking 11 miles per day continued, weight hit
601103 - 165, ref SDS 55 TZ8U; ask where to get lab at VA Martinez, in San
601104 - Francisco, or at UCSF. ref SDS 55 TZ96 No side effects from
601105 - Atorvastatin and Ezetimibe. ref SDS 55 TZ99
601107 - ..
601108 - On 140131 0815 have not received instructions from VA on getting lab
601109 - to test LDL-P, so ordered test. ref SDS 56 OO5G lab blood draw at
601110 - Labcorp in Walnut Creek on Ygnacio Valley Road. ref SDS 56 NT6T
601112 - ..
601113 - On 140201 1159 obtained blood draw for Lipid NMR test at Labcor on
601114 - Health Testing Centers order # 27716, ref SDS 57 KQ4L, showing
601115 - "concordance" LDL-P 861, LDL-C 81, HDL 61, TG 68, LDL (pattern A) size
601116 - = large bouyant protective. ref SDS 57 IM9N
601118 - ..
601119 - On 140203 1147 since have not received instructions from VA, obtained
601120 - blood draw at VA in Martinez to cross check Labcorp blood test. 140203
601121 - 1147, ref SDS 58 KK9M, showing LDL-C 93, HDL 58, TG 47, ref SDS 58
601122 - IM9N, indicating "concordance" LDL-P 626, LDL (pattern A) size = large
601123 - bouyant protective. ref SDS 58 QV5G
601125 - ..
601126 - On 140204 1236 letter from VA today, notifies that Progress Notes for
601127 - meeting on 131219, have been posted and are available for customer to
601128 - receive from ROI department. ref SDS 60 HY6O Cause for 6-weeks delay
601129 - issuing Progress Notes not clear in the record. ref SDS 60 V44F VA
601130 - Progress Notes for meeting on 131219, are comprehensive and helpful.
601131 - ref SDS 60 MR3G Progress Notes have many minor grammatical errors
601132 - likely due to limited time, ref SDS 60 MZ5H, VA does not support NMR
601133 - lipid tests to determine LDL-P and discordance with LDL-C; patient can
601134 - obtain test from another lab. ref SDS 60 CE80 VA letter today
601135 - maintains discordance with low LDL-P and high LDL-C is "unhealthy" -
601136 - submits no evidence from medical literature supporting this
601137 - proposition, nor to address literature submitted to the VA stating
601138 - discordance is the healthiest condition for CVD patients. ref SDS 60
601139 - 6U4L VA concurs that lowering weight toward BMI standards aids
601140 - resolving hyperlipidemia. ref SDS 60 8N9H VA maintains lifestyle
601141 - through exercise and diet to control weight and hyperlipidemia require
601142 - support taking statin medications, e.g., Atorvastatin and Ezetimibe.
601143 - ref SDS 60 GT5F VA letter today says patient mis-reads literature on
601144 - discordance between LDL-P and LDL-C, and proposes discussions to
601145 - clarify this matter during meeting scheduled on 140213. ref SDS 60 HU5M
601146 - VA prefers patient get labs drawn at San Francisco VA Medical Center.
601147 - ref SDS 60 PT3M
601149 - ..
601150 - On 140213 0830 meeting VA San Francisco, ref SDS 63 195I, report good
601151 - progress lowering risks of recurrant CVD based on concordant low LDL-P
601152 - 861 with low LDL-C 81. shown by lab NMR lipid panal. ref SDS 63 TB6J
601153 - Medical team excellent results collaborating doctor/patient
601154 - partnership. ref SDS 63 1L7M Atorvastatin 40 mg started 131121, and
601155 - then changed to Atorvastatin 10 mg with Ezetimibe 10 mg started
601156 - 131230. ref SDS 63 IE7F No side effects taking medication past 6
601157 - weeks. ref SDS 63 333L Objectives and ramifications of discordance
601158 - between LDL-P and LDL-C discussed. ref SDS 63 WM8J Regression of
601159 - atherosclerosis plaque can be assessed with CT and IVUS modalities to
601160 - evaluate recovery from prior acute condition that required surgery in
601161 - 2009. ref SDS 63 JZ4O Will continue medication, diet, exercise and
601162 - weight loss protocols, and test lipid panal again in 3 months on
601163 - 140519 0800. ref SDS 63 8X5O Did not discuss today elevated potasium
601164 - and bilirubin. ref SDS 63 GT7G
601166 - ..
601167 - On 140226 1332 letter to VA transmits notes of meeting on 140213.
601168 - ref SDS 65 HY6O Report possible cold symptoms side effects taking
601169 - Atorvastatin with Ezetimibe. ref SDS 65 JY8K Request consideration
601170 - order CT radiology assess regression atherosclerosis. ref SDS 65 JR99
601171 - Request Progress Notes meeting on 140213. ref SDS 65 JY4M
601173 - ..
601174 - On 140303 1644 letter to VA reports recovery from symptoms of cold,
601175 - which may indicate this was not caused by prescribed medication side
601176 - effects taking Atorvastatin and Ezetimibe. ref SDS 0 HY6O Letter
601177 - requests Progress Notes for meeting a few weeks ago at Medical Center
601178 - in San Francisco. ref SDS 0 E788
601179 -
601180 -
601181 -
601183 - ..
6012 -
6013 -
6014 - Progress
6015 -
601501 - Cold Symptoms Subside Evidence Not Caused Atorvastatin Ezetimibe
601502 -
601503 - Follow up ref SDS 65 HY6O, ref SDS 63 HY6O.
601504 -
601505 - Sent letter to San Francisco VA Medical Center saying...
601506 -
601507 - 1. Subject: Meeting 13 Feb Progress Notes
601508 - Date: 2014-03-03 16:53
601515 - ..
601516 - 2. Good news - cold symptoms reported in the letter on 140226,
601517 - below, have mostly subsided. Only missed 4 days hiking, so
601518 - back on track.
601520 - ..
601521 - Follows up letter notifying VA of symptoms side effects, reported to
601522 - VA on 140226 1332. ref SDS 65 JY8K
601523 -
601524 - [On 130305 1117 VA reports pleased symptoms of illness have
601525 - subsided. ref SDS 68 HY6O
601526 -
601528 - ..
601529 - Progress Notes Request for Meeting San Francisco VA Medical Center
601530 -
601531 -
601532 - Letter to VA continues...
601534 - ..
601535 - 3. Visited ROI in at VA in Martinez. Blis has been reassigned,
601536 - since receiving the request for records last week. Kathleen,
601537 - who was exceptional providing timely Progress Notes, has
601538 - transferred to VA at Mather in Sacramento. The new ROI
601539 - attendant, Clark, said the computer records seem mixed up. He
601540 - cannot find anything for our meeting on 140213. Clark asked
601541 - about sending a request to San Francisco VA for the records. I
601542 - suggested holding off on sending an official request.
601544 - ..
601545 - 4. So, no rush, but when time permits, please submit Progress
601546 - Notes.
601548 - ..
601549 - This follows up request in the letter last week on 140226 1332.
601550 - ref SDS 65 JY4M
601551 -
601552 - [On 130305 1117 VA reports Progress Notes for meeting on
601553 - 140213, will be available for customer to review by end of
601554 - week. ref SDS 68 GO9N
601555 -
601561 -
601562 -
601563 -
601564 -
601565 -
601566 -
601567 -
601568 -
601569 -
601570 -
6016 -